
|Videos|August 24, 2017
Is Cabotegravir a Gender-Neutral PrEP Medication?
Author(s)Contagion Editorial Staff
Alex Rinehart, PhD, explains how cabotegravir is a gender-neutral pre-exposure prophylaxis medication.
Advertisement
Alex Rinehart, PhD, Director, Global Prevention Strategy, ViiV Healthcare, explains studies that are underway involving how effective the PrEP medication cabotegravir is in men who have sex with men as well as transgendered women. Dr. Rinehart stresses that he and his team are trying to study efficacy in all relevant key populations affected by HIV.
Newsletter
Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Contagion Live
1
Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV Meets Primary Endpoint in Phase 3 Study
2
Public Health Wake-Up Call: Will the US Lose Measles Elimination Status?
3
Caring Holistically: NYU’s Approach to Pediatric Infectious Disease
4
Zoliflodacin Emerges as a First-in-Class Oral Option Against Drug-Resistant Gonorrhea
5

















































































































































































































































































